J Hazard Mater. 2025 Jan 24;488:137303. IF: 12.2
Estrogenic and anti-estrogenic assessment of the flame retardant, 2-ethylhexyl diphenyl phosphate (EHDPP), and its metabolites: Evidence from in vitro, in silico, and transcriptome studies.
www.sciencedirect.com/science/article/pii/S0304389425002158
Radiol Med. 2025 Jan 25. IF: 9.7
Superior performance in classification of breast cancer molecular subtype and histological factors by radiomics based on ultrafast MRI over standard MRI: evidence from a prospective study.
link.springer.com/article/10.1007/s11547-025-01956-6
Cell Mol Biol Lett. 2025 Jan 25;30(1):11. IF: 9.2
Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer.
www.biomedcentral.com/articles/10.1186/s11658-025-00694-x
Cancer Lett. 2025 Jan 23. IF: 9.1
Dual targeting PPARα and NPC1L1 metabolic vulnerabilities blocks tumorigenesis.
www.sciencedirect.com/science/article/pii/S0304383525000576
NPJ Breast Cancer. 2025 Jan 26;11:7. IF: 5.9
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.
www.nature.com/articles/s41523-025-00722-1
